Patents by Inventor Susanna M. Rybak
Susanna M. Rybak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7456260Abstract: The current invention provides new human variable chain framework regions and humanized antibodies comprising the framework regions. The invention also provides a new method of identifying framework acceptor regions in framework sequences for backmutation to graft a donor sequence to the human framework.Type: GrantFiled: June 17, 2003Date of Patent: November 25, 2008Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, The University of ReadingInventors: Susanna M. Rybak, Juergen Krauss, Michaela Arndt, Andrew C. R. Martin
-
Patent number: 7189393Abstract: This invention provides for new recombinant ribonuclease proteins which are active when expressed by bacteria. This allows the recombinant ribonucleases of this invention to be fused in-frame with ligand binding moieties to form cytotoxic fusion proteins. Furthermore, these proteins are more active than ribonucleases currently available even though the proteins of this invention lack an N-terminal pyroglutamic acid, which has been found to be necessary for ribonucleolytic activity. Because these proteins are recombinant proteins, mutations which increase cytotoxicity can be engineered.Type: GrantFiled: September 6, 2001Date of Patent: March 13, 2007Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Susanna M. Rybak, Dianne L. Newton
-
Patent number: 7029899Abstract: This invention provides RNase A superfamily polypeptides with modified amino terminal which can be used to selectively kill target Kaposi's sarcoma cells, neoplastic endothelial cells, and non-neoplastic endothelial cells. In certain embodiments of the invention, the amino terminal modification consists of an addition of 4 amino acid sequence consisting of the SLHV sequence at position ?4 to ?1 to the eosinophil derived neurotoxin protein. The amino terminal addition is capable of directing the claimed RNase A superfamily polypeptides to proliferating endothelial cells, such as Kaposi's sarcoma cells, and selectively killing these cells.Type: GrantFiled: November 1, 1999Date of Patent: April 18, 2006Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Susanna M. Rybak, Dianne L. Newton
-
Patent number: 6869604Abstract: This invention provides for new recombinant ribonuclease proteins which are active when expressed by bacteria. This allows the recombinant ribonucleases of this invention to be fused in-frame with ligand binding moieties to form cytotoxic fusion proteins. Furthermore, these proteins are more active than ribonucleases currently available even though the proteins of this invention lack an N-terminal pyroglutamic acid, which has been found to be necessary for ribonucleolytic activity. Because these proteins are recombinant proteins, mutations which increase cytotoxicity can be engineered.Type: GrantFiled: March 26, 1999Date of Patent: March 22, 2005Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Susanna M. Rybak, Dianne L. Newton
-
Publication number: 20040117863Abstract: A method of making a transgenic fusion protein. The method inlcudes providing a transgenic animal which includes a transgene which provides for the expression of the fusion protein; allowing the transgene to be expressed; and, recovering the fusion protein, from the milk of the transgenic animal.Type: ApplicationFiled: June 27, 2003Publication date: June 17, 2004Inventors: Michael D. Edge, Dan Pollock, Yann Echelard, Harry M. Meade, Susanna M. Rybak
-
Publication number: 20030124131Abstract: This invention provides for new recombinant ribonuclease proteins which are active when expressed by bacteria. This allows the recombinant ribonucleases of this invention to be fused in-frame with ligand binding moieties to form cytotoxic fusion proteins. Furthermore, these proteins are more active than ribonucleases currently available even though the proteins of this invention lack an N-terminal pyroglutamic acid, which has been found to be necessary for ribonucleolytic activity. Because these proteins are recombinant proteins, mutations which increase cytotoxicity can be engineered.Type: ApplicationFiled: September 25, 2001Publication date: July 3, 2003Inventors: Susanna M. Rybak, David M. Goldenberg, Dianne L. Newton
-
Publication number: 20030114368Abstract: The present invention relates to immunotoxins, that effectively kill malignant cells having a given surface marker and nucleic acid constructs encoding them. These reagents comprise a toxic moiety that is derived from a Rana pipiens protein having ribonucleolytic activity linked to an antibody capable of specific binding with a chosen tumor cell.Type: ApplicationFiled: July 30, 2001Publication date: June 19, 2003Applicant: SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: Susanna M. Rybak, Dianne L. Newton, David M. Goldenberg
-
Publication number: 20030027311Abstract: This invention provides for new recombinant ribonuclease proteins which are active when expressed by bacteria. This allows the recombinant ribonucleases of this invention to be fused in-frame with ligand binding moieties to form cytotoxic fusion proteins. Furthermore, these proteins are more active than ribonucleases currently available even though the proteins of this invention lack an N-terminal pyroglutamic acid, which has been found to be necessary for ribonucleolytic activity. Because these proteins are recombinant proteins, mutations which increase cytotoxicity can be engineered.Type: ApplicationFiled: September 6, 2001Publication date: February 6, 2003Applicant: The Department of Health and Human Services National Institutes of HealthInventors: Susanna M. Rybak, Dianne L. Newton
-
Patent number: 6395276Abstract: The present invention relates to immunotoxins, that effectively kill malignant cells having a given surface marker and nucleic acid constructs encoding them. These reagents comprise a toxic moiety that is derived from a Rana pipiens protein having ribonucleolytic activity linked to an antibody capable of specific binding with a chosen tumor cell.Type: GrantFiled: May 1, 1998Date of Patent: May 28, 2002Assignee: Immunomedics, Inc.Inventors: Susanna M. Rybak, Dianne L. Newton, David M. Goldenberg
-
Patent number: 6045793Abstract: The invention relates to ribonucleases derived from a native ribonuclease found in the oocytes of Rana pipiens. Various humanized and recombinant forms of these molecules are described as well as uses for them.Type: GrantFiled: February 19, 1998Date of Patent: April 4, 2000Inventors: Susanna M. Rybak, Dianne L. Newton, Lluis Boque, Alexander Wlodawer
-
Patent number: 5955073Abstract: The present invention relates to a selective cytotoxic RNase reagent. The reagent comprises a toxic moiety that is an RNase linked to a recognition moiety that binds a specific cell surface marker. Binding of the recognition moiety to a surface marker on a cell allows the toxic moiety to selectively kill the cell. To reduce immunogenicity, preferably the toxic moiety and the recognition moiety of the conjugate are endogenous to the species in which the reagent is intended for use. Cytotoxic reagents intended for use in humans preferably have as the toxic moiety a human ribonuclease, such as angiogenin, and as the recognition moiety as humanized chimeric antibody. The human ribonuclease and chimeric antibody preferably form a fused protein. The present invention also relates to pharmaceutical compositions including the cytotoxic reagent as well as treatment methods involving the use of the cytotoxic reagent.Type: GrantFiled: July 9, 1997Date of Patent: September 21, 1999Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Susanna M. Rybak, Richard J. Youle, Dianne L. Newton, Peter J. Nicholls
-
Patent number: 5840840Abstract: The present invention relates to a selective cytotoxic RNase reagent. The reagent comprises a toxic moiety that is an RNase linked to a recognition moiety that binds a specific cell surface marker. Binding of the recognition moiety to a surface marker on a cell allows the toxic moiety to selectively kill the cell. To reduce immunogenicity, preferably the toxic moiety and the recognition moiety of the conjugate are endogenous to the species in which the reagent is intended for use. Cytotoxic reagents intended for use in humans preferably have as the toxic moiety a human ribonuclease, such as angiogenin, and as the recognition moiety as humanized chimeric antibody. The human ribonuclease and chimeric antibody preferably form a fused protein. The present invention also relates to pharmaceutical compositions including the cytotoxic reagent as well as treatment methods involving the use of the cytotoxic reagent.Type: GrantFiled: September 22, 1993Date of Patent: November 24, 1998Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Susanna M. Rybak, Richard J. Youle, Dianne L. Newton, Peter J. Nicholls